A phase I trial of LX-101 in patients with advanced, pretreated solid and hematologic cancers
Latest Information Update: 29 Feb 2024
At a glance
- Drugs LX 101 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 26 Feb 2024 Results published in the Lirum Therapeutics Media Release.
- 26 Feb 2024 According to a Lirum Therapeutics media release, the data from this trial will be presented at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).
- 05 Jun 2023 Results presented in a Lirum Therapeutics Media Release.